857070-67-8

Basic information

• Product Name: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol
• Synonyms: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol;[2-(3-morpholin-4-ylpropylamino)-3H-benzimidazol-5-yl]methanol
• CAS NO: 857070-67-8
• Molecular Formula: C15H22N4O2
• Molecular Weight: 290.36078
• Mol File: 857070-67-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol(857070-67-8)
• EPA Substance Registry System: (2-((3-Morpholinopropyl)aMino)-1H-benzo[d]iMidazol-6-yl)Methanol(857070-67-8)

Safety Data

• Hazardous Substances Data: 857070-67-8(Hazardous Substances Data)

Usage

Description

(2-((3-Morpholinopropyl)amino)-1H-benzo[d]imidazol-6-yl)methanol is a benzimidazole derivative that features a morpholinopropylamine group and a methanol moiety. This chemical compound holds potential pharmaceutical applications due to its structural characteristics, which suggest an affinity for adrenergic and serotonergic receptors in the central nervous system. This makes it a promising candidate for the treatment of psychiatric and neurological disorders.

Uses

Used in Pharmaceutical Industry:
(2-((3-Morpholinopropyl)amino)-1H-benzo[d]imidazol-6-yl)methanol is used as a potential therapeutic agent for the treatment of psychiatric and neurological disorders. Its structure allows it to potentially interact with adrenergic and serotonergic receptors in the central nervous system, which could contribute to its efficacy in managing such conditions.
Further research and testing are required to fully understand the pharmacological properties and potential therapeutic uses of this compound, ensuring its safety and effectiveness in clinical applications.

Upstream product

• 123-00-2 4-(3-Aminopropyl)morpholine 
• 857035-29-1 2-chloro-3H-benzoimidazole-5-carboxylic acid ethyl ester 
• 37466-90-3 ethyl 3,4-diaminobenzoate 
• 634602-84-9 2-hydroxy-3H-benzoimidazole-5-carboxylic acid ethyl ester 
• 857070-66-7 (2-chloro-3H-benzoimidazol-5-yl)methanol 

Downstream Products

• 857070-65-6 3-(3-hydroxy-6-methylpyridin-2-ylmethyl)-2-(3-morpholin-4-ylpropylamino)-3H-benzoimidazole-5-carbaldehyde 
• 857067-39-1 2-[5-hydroxymethyl-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl]-6-methylpyridin-3-ol 
• 857067-38-0 2-[6-hydroxymethyl-2-(3-morpholin-4-ylpropylamino)benzoimidazol-1-ylmethyl]-6-methylpyridin-3-ol 

Relevant articles and documents

Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121)

A preceding paper (Bonfanti et al. J. Med Chem. 2007, 50, 4572-4584) reported the optimization of the pharmacokinetic profile of substituted benzimidazoles by reducing their tissue retention. However, the modifications that were necessary to achieve this goal also led to a significant drop in anti-RSV activity. This paper describes a molecular modeling study followed by a lead optimization program that led to the recovery of the initial potent antiviral activity and the selection of TMC353121 as a clinical candidate.

MORPHOLINYL CONTAINING BENZIMIDAZOLES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION

The present invention concerns morpholinyl containing benzimidazoles having inhibitory activity on the replication of the respiratory syncytial virus and having the formula (I), a prodrug, N-oxide, addition salt, quaternary amine, metal complex or stereoc